Aprepitant
APONVIE, CINVANTI, EMEND
Substance P/Neurokinin-1 Receptor Antagonist
NADAC/unit
$42.4485
No Shortage
Tier 1: 81.2%
PA Req: 412.8%
4 Manufacturers
10 ANDAs
vs. brand APONVIE: Generic saves up to -324% per unit
Market Intelligence
2025-12-31 Class II Recall: Merck Sharp & Dohme LLC
Generic Manufacturers
GLENMARK SPECIALTY SAHERON THERAPEUTICS INCMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INCMERCK SHARP AND DOHME LLCMYLAN PHARMACEUTICALS INCSANDOZ INCTORRENT PHARMA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.